Dominick Angiolillo
Latest contributions
Redefining complex PCI: impact of real-world data and novel evidence on IV antithrombotic strategies
21 May 2025 – From EuroPCR 2025
Explore how real-world data and evolving evidence are reshaping IV antithrombotic strategies in complex PCI. This EuroPCR 2025 session brings together urgent clinical cases—including STEMI patients in shock—and highlights key insights from the SMILE registry. Learn how transition protocols from cangrelor to oral P2Y12 inhibitors are...
Post PCI anti-thrombotic strategies
15 May 2024 – From EuroPCR 2024
These papers changed my practice!
18 May 2023 – From EuroPCR 2023
Consult this session if you want to reflect on practical teachings from key papers of leading journals in 2022, to watch real cases translating science into practice, and to meet the editors of EuroIntervention and JACC: Cardiovascular Interventions.
How to optimise peri-PCI antiplatelet treatment in clinical practice? Novel evidence on cangrelor
17 May 2023 – From EuroPCR 2023
Discover the optimal approach to peri-percutaneous coronary intervention (PCI) antiplatelet treatment in clinical practice with a focus on the novel agent cangrelor. Gain a deeper understanding of the rationale behind cangrelor's use in various PCI settings, learn about the current recommendations and practices for its administration...
PCR Spotlight: antithrombotic and anticoagulant treatment in the COVID-19 era
18 May 2020
D Capodanno, G Montalescot, and D Angiolillo discuss how to manage antithrombotic therapy in patients with COVID-19 undergoing interventional procedures.
How to manage PCI in patients treated with oral anticoagulants
PCROnline Editor Davide Capodanno raises the hot topic of how to manage antithrombotic therapy in patients with atrial fibrillation who need dual antiplatelet therapy. He asks Dominick Angiolillo from the USA for practical advice about which anticoagulants and P2Y12 inhibitors to use, and the most difficult...
Trials and registries - Managing bleeding risk in search of optimal drug-device synergy
23 May 2019 – From EuroPCR 2019
Consult this session to discover the results of the latest trials and registries for the management of bleeding risk in search of optimal drug-device synergy: ROBOT-ACS, GLOBAL LEADERS, SAFE-A, and more!
How to manage PCI in patients treated with oral anticoagulant?
22 May 2019 – From EuroPCR 2019
Consult this session to learn how to decide between different combinations of antithrombotic agents after PCI and how to manage high ischaemic risk patients treated with oral anticoagulant.
Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease
22 May 2019 – From EuroPCR 2019
Consult this session to learn more about the cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonists in patients with diabetes and coronary artery disease, and the clinical strategy for treatment implementation.
Bridging the gap of oral P2Y12 inhibition for PCI with cangrelor: what does the new data tell us?
22 May 2019 – From EuroPCR 2019
Consult this session to learn through studies and clinical cases more about contemporary pharmacological strategies with intravenous antiplatelet therapy in PCI for STEMI, NSTEMI and complex stable coronary artery disease patients.
